Devyser receives EUR 750,000 Eurostars grant to develop novel DNA test for early detection of transplant rejection
Stockholm, January 19, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that it has been awarded funding through the Eurostars-2 program for the further development of its unique Next-Generation Sequencing based test for surveillance of graft status and early diagnosis of rejection in kidney transplant recipients. The grant awarded is EUR 750,000.The ENVISAGE project is a consortium between Devyser and the University Hospital of Zurich (UHZ), aiming to further develop and perfect Devyser’s proprietary Next-Generation Sequencing (NGS) based test